# Cartography Biosciences

Source: https://onco.cc/companies/cartography-biosciences/  
OnCo record `cartography-biosciences` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Cartography Biosciences searches huge maps of single human cells for proteins found only on cancer cells, then builds antibody medicines that steer immune T cells to them; its first drug is in an early trial in bowel cancer.

## Summary

Cartography Biosciences, based in South San Francisco and founded by Kevin Parker, Ansu Satpathy and Howard Chang, uses two platforms, ATLAS and SUMMIT, which apply machine learning to single-cell data from healthy and tumour tissue to find targets and target combinations specific to cancer cells. CBI-1214, a T cell engager against an undisclosed novel target, received FDA IND clearance and Fast Track designation in December 2025 and dosed its first patient in a phase 1 trial in microsatellite-stable or MSI-low metastatic colorectal cancer in February 2026 (NCT07321106). CB02 is a preclinical T cell engager, and discovery programmes include logic-gated approaches. It has discovery collaborations with Gilead (announced May 2024; first target option exercised April 2026) and Pfizer (January 2026). Its first registered cancer trial, NCT07321106, was posted on ClinicalTrials.gov in January 2026.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- HQ: South San Francisco, CA
- Type: biotech
- Website: https://cartography.bio/

## Notes

- Company website, pipeline and news page read on 29 October 2026. Founding year not stated on the pages read. The company news page links a October 2025 Business Wire release headlined as a USD 67 million Series B and a May 2026 strategic investment from Samsung Ventures, but those releases refused automated reading, so no funding rows are recorded.

## Sources

- Official website: https://cartography.bio/
- Pipeline: https://cartography.bio/pipeline/
- News: https://cartography.bio/news/
- ClinicalTrials.gov: phase 1 trial of CBI-1214 (NCT07321106): https://clinicaltrials.gov/study/NCT07321106

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- fronts: [AI & Computation](https://onco.cc/fronts/ai-computation/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/), [Logic-gated therapeutics (AND, NOT gates)](https://onco.cc/technologies/logic-gated-therapeutics/), [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)

---
JSON: https://onco.cc/api/v1/entities/cartography-biosciences.json